营收近80亿，东晓生物获批登陆新三板！以合成生物和发酵技术深耕多元产品领域

Core Viewpoint - The article highlights the progress of Dongxiao Biotechnology Co., Ltd. in the synthetic biology manufacturing sector, focusing on its diverse corn deep processing capabilities and its upcoming listing on the New Third Board [2][4]. Group 1: Company Overview - Dongxiao Biotechnology specializes in synthetic biology manufacturing and fermentation technology, primarily engaged in the deep processing of corn to produce animal nutrition products, solid beverages, food additives, organic acids, and health sweeteners [2][4]. - The company has an annual corn deep processing capacity of 1.6 million tons, producing various products such as L-lysine hydrochloride, erythritol, and glucose [4]. Group 2: Market Position and Innovation - Dongxiao is positioned as a leader in the corn deep processing industry, transforming traditional agricultural raw materials into high-value products through technological innovation [4]. - The company utilizes renewable resources like corn and green energy sources such as wind and solar power to achieve sustainable product transformation across multiple sectors, including food, pharmaceuticals, and personal care [4]. Group 3: Financial Performance - For the fiscal years 2023 and 2024, Dongxiao's projected revenues are 7.993 billion yuan and 7.840 billion yuan, respectively, with main business revenues contributing significantly at 7.845 billion yuan and 7.630 billion yuan, accounting for 98.15% and 97.33% of total revenues [5]. - The net profits for the same periods are expected to be 298 million yuan and 578 million yuan, with a slight decline in revenue attributed to lower procurement prices for corn and energy [5]. - The overall gross profit margin is projected to improve to 10.33% and 13.91%, driven by reduced raw material costs despite limited price declines in the market [5].